Full-Time
Experimental Crisprx Platform Developer
Confirmed live in the last 24 hours
Vevo Therapeutics
11-50 employees
AI-driven in vivo drug discovery platform
Compensation Overview
$120k - $145kAnnually
Senior, Expert
San Bruno, CA, USA
- In-depth experience in having run CRISPRx screens for target deconvolution, ideally paired i/a or KO/a screening
- Experience in scaling screening operations and training others
- Experience in method development in the CRISPRx space whether combinatorial screening, Perturb/Crop-seq based screening, etc.
- Experience and familiarity with programming for CRISPR screen analysis
- Experience and familiarity in building out oncology stories by interpreting screen data, generating knockdown/out lines, and assessing efficacy using dose-response, in-vivo xenograft, and biochemical assays in an oncology setting
- Experience in a fast paced environment and ability to work quickly to achieve company goals
- Ph.D in relevant discipline required
- Lead and execute CRISPR screens at high-throughput at Vevo
- Scale and develop robust experimental/computational pipelines for conducting drug MOA deconvolution screens
- Validate targets discovered from screens using traditional oncology assays
- Develop new methods in the CRISPRx screening space in conjunction with Vevo’s proprietary Mosaic single-cell multiplexed platform
Vevo Therapeutics uses advanced AI models and its Mosaic platform to enhance drug discovery by generating high-resolution in vivo data, which studies drug interactions within living organisms. This method allows for the identification of new drug targets and candidates that traditional techniques might miss. The company serves pharmaceutical and biotech firms by providing insights into drug efficacy and gene expression at a single-cell level, making the drug discovery process faster and more cost-effective. Vevo's goal is to improve drug development, leading to better treatments for a broader range of patients.
Company Stage
Seed
Total Funding
$12M
Headquarters
San Francisco, California
Founded
2022
6 month growth
↓ -7%1 year growth
↑ 9%2 year growth
↑ 71%
Simplify's Take
What believers are saying
- The $12M seed funding led by General Catalyst and Wing Venture Capital provides a strong financial foundation for scaling operations and advancing research.
- Vevo's innovative approach promises to uncover novel drug targets and candidates, potentially leading to breakthrough therapies and significant advancements in patient outcomes.
- Partnerships with pharmaceutical and biotech companies can offer tailored solutions, enhancing the company's market reach and revenue potential.
What critics are saying
- The biotechnology and pharmaceutical markets are highly competitive, requiring continuous innovation to maintain a leading edge.
- Reliance on advanced AI models and proprietary technology may pose challenges in terms of technological integration and data accuracy.
What makes Vevo Therapeutics unique
- Vevo Therapeutics leverages its proprietary Mosaic platform to generate high-resolution in vivo data, offering a more accurate picture of drug interactions within living organisms compared to traditional in vitro methods.
- The company's focus on single-cell RNA profiling across diverse patient samples allows for a comprehensive understanding of drug efficacy and gene expression changes, setting it apart from competitors.
- Vevo's integration of advanced AI models with in vivo data generation accelerates the drug discovery process, making it more cost-effective and scalable.